ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Garrett L. Walsh
Jonathan C. Nesbitt
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walsh, G. L.
Right arrow Articles by Amato, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walsh, G. L.
Right arrow Articles by Amato, R. J.
Related Collections
Right arrowRelated Article

Ann Thorac Surg 2000;69:337-343
© 2000 The Society of Thoracic Surgeons


Original Articles

Intensive chemotherapy and radical resections for primary nonseminomatous mediastinal germ cell tumors

Garrett L. Walsh, MDa, Grant D. Taylor, BSa, Jonathan C. Nesbitt, MDa, Robert J. Amato, MDa

a Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

Address reprint requests to Dr Walsh, Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Box 109, 1515 Holcombe Blvd, Houston, TX 77030

Presented at the Thirty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, Jan 25–27, 1999.

Background. Primary nonseminomatous germ cell tumors of the mediastinum (PNSGM), unlike malignancies of gonadal origin, have a poor prognosis. We report a single institutional experience over a 5-year period of PNSGM treated with intensive chemotherapy, followed by radical operation in those who responded to this neoadjuvant regimen.

Methods. From 1993 to 1998, 20 patients were referred for the management of PNSGM. All were male, with a median age of 30.5 years (range 18 to 48). Eighteen of 20 (90%) presented with symptoms. Most tumors were large, with a median diameter of 10 cm (range 3 to 20 cm). Thirteen patients (65%) had metastatic disease at the time of presentation. Eleven patients had received no prior treatment (initial group) and 9 were referred for salvage therapy after progression of their tumors, following treatment at other facilities (salvage group). All had elevated serum tumor markers (ßhCG and {alpha}-fetoprotein). Preoperative chemotherapy included alternating cycles of combinations of 3 or more drugs, including cisplatin, bleomycin, etoposide, vincristine, methotrexate, actinomycin, cyclophosphamide, and doxorubicin. An average of 10 cycles of chemotherapy was given to each patient in the initial group, and six to those in the salvage group. Five patients (25%) developed transient renal insufficiency, and 35% developed pulmonary infiltrates related to bleomycin. There were 3 chemotherapy related deaths.

Results. After chemotherapy, 11 patients underwent operation, with 10 complete resections of the residual mediastinal tumors. There were no perioperative deaths. The 2-year survival in the initial group is 72%, and 42% for the salvage group.

Conclusions. An aggressive, multidisciplinary approach of alternating cycles of chemotherapy, followed by complete surgical resection of all remaining disease in patients whose markers normalize, can be associated with prolonged survival in patients with PNSGM.


Related Article

Discussion
Ann. Thorac. Surg. 2000 69: 343-344. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
K. A. Kesler, K. M. Rieger, Z. T. Hammoud, L. E. Kruter, S. M. Perkins, M. W. Turrentine, B. P. Schneider, L. H. Einhorn, and J. W. Brown
A 25-Year Single Institution Experience With Surgery for Primary Mediastinal Nonseminomatous Germ Cell Tumors
Ann. Thorac. Surg., February 1, 2008; 85(2): 371 - 378.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
C. H. Kang, Y. T. Kim, S.-H. Jheon, S.-w. Sung, and J. H. Kim
Surgical Treatment of Malignant Mediastinal Nonseminomatous Germ Cell Tumor
Ann. Thorac. Surg., February 1, 2008; 85(2): 379 - 384.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
H. Date, K. Kiura, H. Ueoka, M. Tabata, K. Hotta, H. Katayama, I. Kataoka, and M. Tanimoto
Induction chemotherapy, surgical resection, and high-dose chemotherapy for mediastinal nonseminomatous germ-cell tumor
J. Thorac. Cardiovasc. Surg., October 1, 2005; 130(4): 1205 - 1206.
[Full Text] [PDF]


Home page
ChestHome page
B. V. Duwe, D. H. Sterman, and A. I. Musani
Tumors of the Mediastinum
Chest, October 1, 2005; 128(4): 2893 - 2909.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
H. Sakurai, H. Asamura, K. Suzuki, S.-i. Watanabe, and R. Tsuchiya
Management of Primary Malignant Germ Cell Tumor of the Mediastinum
Jpn. J. Clin. Oncol., July 1, 2004; 34(7): 386 - 392.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2000 by The Society of Thoracic Surgeons.